ID   EPN1_RAT                Reviewed;         575 AA.
AC   O88339;
DT   16-JAN-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   29-MAY-2024, entry version 186.
DE   RecName: Full=Epsin-1;
DE   AltName: Full=EPS-15-interacting protein 1;
GN   Name=Epn1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND INTERACTION WITH EPS15; AP2A1 AND AP2A2.
RC   STRAIN=Wistar; TISSUE=Brain;
RX   PubMed=9723620; DOI=10.1038/29555;
RA   Chen H., Fre S., Slepnev V.I., Capua M.R., Takei K., Butler M.H.,
RA   Di Fiore P.P., De Camilli P.;
RT   "Epsin is an EH-domain-binding protein implicated in clathrin-mediated
RT   endocytosis.";
RL   Nature 394:793-797(1998).
RN   [2]
RP   TISSUE SPECIFICITY.
RX   PubMed=10393179; DOI=10.1093/emboj/18.13.3629;
RA   Nakashima S., Morinaka K., Koyama S., Ikeda M., Kishida M., Okawa K.,
RA   Iwamatsu A., Kishida S., Kikuchi A.;
RT   "Small G protein Ral and its downstream molecules regulate endocytosis of
RT   EGF and insulin receptors.";
RL   EMBO J. 18:3629-3642(1999).
RN   [3]
RP   INTERACTION WITH AP2A2.
RX   PubMed=10380931; DOI=10.1016/s0092-8674(00)80791-6;
RA   Owen D.J., Vallis Y., Noble M.E.M., Hunter J.B., Dafforn T.R., Evans P.R.,
RA   McMahon H.T.;
RT   "A structural explanation for the binding of multiple ligands by the alpha-
RT   adaptin appendage domain.";
RL   Cell 97:805-815(1999).
RN   [4]
RP   PHOSPHORYLATION, AND INTERACTION WITH AP-2.
RX   PubMed=9920862; DOI=10.1074/jbc.274.6.3257;
RA   Chen H., Slepnev V.I., Di Fiore P.P., De Camilli P.;
RT   "The interaction of epsin and Eps15 with the clathrin adaptor AP-2 is
RT   inhibited by mitotic phosphorylation and enhanced by stimulation-dependent
RT   dephosphorylation in nerve terminals.";
RL   J. Biol. Chem. 274:3257-3260(1999).
RN   [5]
RP   INTERACTION WITH AP2A2.
RX   PubMed=10430869; DOI=10.1073/pnas.96.16.8907;
RA   Traub L.M., Downs M.A., Westrich J.L., Fremont D.H.;
RT   "Crystal structure of the alpha appendage of AP-2 reveals a recruitment
RT   platform for clathrin-coat assembly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:8907-8912(1999).
RN   [6]
RP   INTERACTION WITH AP2B1.
RX   PubMed=10944104; DOI=10.1093/emboj/19.16.4216;
RA   Owen D.J., Vallis Y., Pearse B.M.F., McMahon H.T., Evans P.R.;
RT   "The structure and function of the beta 2-adaptin appendage domain.";
RL   EMBO J. 19:4216-4227(2000).
RN   [7]
RP   MUTAGENESIS OF 257-LEU--ASP-259 AND 260-LEU--VAL-263, SUBCELLULAR LOCATION,
RP   AND INTERACTION WITH CLATHRIN HEAVY CHAIN AND AP-2.
RX   PubMed=10692452; DOI=10.1074/jbc.275.9.6479;
RA   Drake M.T., Downs M.A., Traub L.M.;
RT   "Epsin binds to clathrin by associating directly with the clathrin-terminal
RT   domain. Evidence for cooperative binding through two discrete sites.";
RL   J. Biol. Chem. 275:6479-6489(2000).
RN   [8]
RP   FUNCTION, INTERACTION WITH ZBTB16, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ARG-8; ARG-63; ARG-72 AND LYS-76.
RX   PubMed=11161217; DOI=10.1126/science.291.5506.1047;
RA   Itoh T., Koshiba S., Kigawa T., Kikuchi A., Yokoyama S., Takenawa T.;
RT   "Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding
RT   and endocytosis.";
RL   Science 291:1047-1051(2001).
RN   [9]
RP   MUTAGENESIS OF LEU-190, AND UBIQUITINATION.
RX   PubMed=11919637; DOI=10.1038/416451a;
RA   Polo S., Sigismund S., Faretta M., Guidi M., Capua M.R., Bossi G., Chen H.,
RA   De Camilli P., Di Fiore P.P.;
RT   "A single motif responsible for ubiquitin recognition and
RT   monoubiquitination in endocytic proteins.";
RL   Nature 416:451-455(2002).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-453 AND THR-469, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 12-160, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH ZNF145.
RX   PubMed=10791968; DOI=10.1083/jcb.149.3.537;
RA   Hyman J., Chen H., Di Fiore P.P., De Camilli P., Brunger A.T.;
RT   "Epsin 1 undergoes nucleocytosolic shuttling and its eps15 interactor
RT   NH(2)-terminal homology (ENTH) domain, structurally similar to Armadillo
RT   and Heat repeats, interacts with the transcription factor promyelocytic
RT   leukemia Zn(2)+ finger protein (PLZF).";
RL   J. Cell Biol. 149:537-546(2000).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-158 IN COMPLEX WITH
RP   INOSITOL-1,4,5-TRIPHOSPHATE, FUNCTION, AND MUTAGENESIS OF LEU-6; ARG-63 AND
RP   HIS-73.
RX   PubMed=12353027; DOI=10.1038/nature01020;
RA   Ford M.G.J., Mills I.G., Peter B.J., Vallis Y., Praefcke G.J.K.,
RA   Evans P.R., McMahon H.T.;
RT   "Curvature of clathrin-coated pits driven by epsin.";
RL   Nature 419:361-366(2002).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 375-381 IN COMPLEX WITH AP2A2.
RX   PubMed=12057195; DOI=10.1016/s0969-2126(02)00784-0;
RA   Brett T.J., Traub L.M., Fremont D.H.;
RT   "Accessory protein recruitment motifs in clathrin-mediated endocytosis.";
RL   Structure 10:797-809(2002).
CC   -!- FUNCTION: Binds to membranes enriched in phosphatidylinositol 4,5-
CC       bisphosphate (PtdIns(4,5)P2) (PubMed:11161217). Modifies membrane
CC       curvature and facilitates the formation of clathrin-coated
CC       invaginations (PubMed:12353027, PubMed:9723620). Regulates receptor-
CC       mediated endocytosis (By similarity). {ECO:0000250|UniProtKB:Q9Y6I3,
CC       ECO:0000269|PubMed:11161217, ECO:0000269|PubMed:12353027,
CC       ECO:0000269|PubMed:9723620}.
CC   -!- SUBUNIT: Monomer. Binds ITSN1 (By similarity). Binds clathrin,
CC       ZBTB16/ZNF145, AP2A1 and AP2A2. Binds ubiquitinated proteins. Interacts
CC       with RALBP1 in a complex also containing NUMB and TFAP2A during
CC       interphase and mitosis. Interacts with AP2B1. Interacts with UBQLN2 (By
CC       similarity). Interacts with REPS2; the interaction is direct (By
CC       similarity). Interacts with EPS15; the interaction is direct (By
CC       similarity). Interacts with ENTREP1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q80VP1, ECO:0000250|UniProtKB:Q9Y6I3,
CC       ECO:0000269|PubMed:10380931, ECO:0000269|PubMed:10430869,
CC       ECO:0000269|PubMed:10692452, ECO:0000269|PubMed:10791968,
CC       ECO:0000269|PubMed:10944104, ECO:0000269|PubMed:11161217,
CC       ECO:0000269|PubMed:12057195, ECO:0000269|PubMed:12353027,
CC       ECO:0000269|PubMed:9723620, ECO:0000269|PubMed:9920862}.
CC   -!- INTERACTION:
CC       O88339; P39083: RGA1; Xeno; NbExp=2; IntAct=EBI-7066728, EBI-15044;
CC       O88339; Q06407: RGA2; Xeno; NbExp=2; IntAct=EBI-7066728, EBI-15060;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral membrane
CC       protein. Nucleus. Membrane, clathrin-coated pit. Note=Associated with
CC       the cytoplasmic membrane at sites where clathrin-coated pits are
CC       forming. Colocalizes with clathrin and AP-2 in a punctate pattern on
CC       the plasma membrane. Colocalizes with clathrin at the Golgi complex.
CC       Detected in presynaptic nerve terminals and in synaptosomes. May
CC       shuttle to the nucleus when associated with ZBTB16/ZNF145.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed (PubMed:9723620). Detected
CC       in liver, spleen and testis, and weakly in lung and thymus (at protein
CC       level) (PubMed:10393179). {ECO:0000269|PubMed:10393179,
CC       ECO:0000269|PubMed:9723620}.
CC   -!- DOMAIN: The NPF repeat domain is involved in EPS15 binding.
CC   -!- DOMAIN: The DPW repeat domain is involved in AP2A2 and clathrin
CC       binding.
CC   -!- DOMAIN: The [DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif mediates interaction
CC       the AP-2 complex subunit AP2B1. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:11919637}.
CC   -!- PTM: Phosphorylated on serine and/or threonine residues in mitotic
CC       cells. Phosphorylation reduces interaction with REPS2, AP-2 and the
CC       membrane fraction. Depolarization of synaptosomes results in
CC       dephosphorylation. {ECO:0000269|PubMed:9920862}.
CC   -!- SIMILARITY: Belongs to the epsin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=The bubble's bend - Issue 42
CC       of January 2004;
CC       URL="https://web.expasy.org/spotlight/back_issues/042";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF018261; AAC33823.1; -; mRNA.
DR   RefSeq; NP_476477.1; NM_057136.1.
DR   PDB; 1EDU; X-ray; 1.80 A; A=12-160.
DR   PDB; 1EYH; X-ray; 1.56 A; A=15-158.
DR   PDB; 1H0A; X-ray; 1.70 A; A=1-158.
DR   PDB; 1KY6; X-ray; 2.00 A; P=375-381.
DR   PDBsum; 1EDU; -.
DR   PDBsum; 1EYH; -.
DR   PDBsum; 1H0A; -.
DR   PDBsum; 1KY6; -.
DR   AlphaFoldDB; O88339; -.
DR   BMRB; O88339; -.
DR   SMR; O88339; -.
DR   BioGRID; 250724; 16.
DR   CORUM; O88339; -.
DR   DIP; DIP-40738N; -.
DR   ELM; O88339; -.
DR   IntAct; O88339; 5.
DR   MINT; O88339; -.
DR   STRING; 10116.ENSRNOP00000021286; -.
DR   iPTMnet; O88339; -.
DR   PhosphoSitePlus; O88339; -.
DR   jPOST; O88339; -.
DR   PaxDb; 10116-ENSRNOP00000021286; -.
DR   PeptideAtlas; O88339; -.
DR   GeneID; 117277; -.
DR   KEGG; rno:117277; -.
DR   UCSC; RGD:619772; rat.
DR   AGR; RGD:619772; -.
DR   CTD; 29924; -.
DR   RGD; 619772; Epn1.
DR   eggNOG; KOG2056; Eukaryota.
DR   HOGENOM; CLU_012678_4_2_1; -.
DR   InParanoid; O88339; -.
DR   OrthoDB; 1532at2759; -.
DR   PhylomeDB; O88339; -.
DR   Reactome; R-RNO-182971; EGFR downregulation.
DR   Reactome; R-RNO-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-RNO-8856828; Clathrin-mediated endocytosis.
DR   EvolutionaryTrace; O88339; -.
DR   PRO; PR:O88339; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030125; C:clathrin vesicle coat; IBA:GO_Central.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0005768; C:endosome; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0098794; C:postsynapse; IDA:SynGO.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:BHF-UCL.
DR   GO; GO:0098793; C:presynapse; IDA:SynGO.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:BHF-UCL.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IDA:SynGO.
DR   GO; GO:0043195; C:terminal bouton; HDA:ParkinsonsUK-UCL.
DR   GO; GO:0035615; F:clathrin adaptor activity; IMP:CAFA.
DR   GO; GO:0030276; F:clathrin binding; IBA:GO_Central.
DR   GO; GO:0140313; F:molecular sequestering activity; ISO:RGD.
DR   GO; GO:0005543; F:phospholipid binding; IBA:GO_Central.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:RGD.
DR   GO; GO:0048268; P:clathrin coat assembly; IDA:DisProt.
DR   GO; GO:0048568; P:embryonic organ development; ISO:RGD.
DR   GO; GO:0006897; P:endocytosis; IDA:RGD.
DR   GO; GO:0007565; P:female pregnancy; ISO:RGD.
DR   GO; GO:0001701; P:in utero embryonic development; ISO:RGD.
DR   GO; GO:0090148; P:membrane fission; IDA:CACAO.
DR   GO; GO:1903671; P:negative regulation of sprouting angiogenesis; ISO:RGD.
DR   GO; GO:0007219; P:Notch signaling pathway; ISO:RGD.
DR   GO; GO:1905445; P:positive regulation of clathrin coat assembly; IMP:CAFA.
DR   CDD; cd16990; ENTH_Epsin; 1.
DR   DisProt; DP00251; -.
DR   Gene3D; 1.25.40.90; -; 1.
DR   InterPro; IPR013809; ENTH.
DR   InterPro; IPR008942; ENTH_VHS.
DR   InterPro; IPR003903; UIM_dom.
DR   PANTHER; PTHR12276:SF48; EPSIN-1; 1.
DR   PANTHER; PTHR12276; EPSIN/ENT-RELATED; 1.
DR   Pfam; PF01417; ENTH; 1.
DR   SMART; SM00273; ENTH; 1.
DR   SMART; SM00726; UIM; 3.
DR   SUPFAM; SSF48464; ENTH/VHS domain; 1.
DR   PROSITE; PS50942; ENTH; 1.
DR   PROSITE; PS50330; UIM; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Coated pit; Cytoplasm; Endocytosis;
KW   Lipid-binding; Membrane; Methylation; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN           1..575
FT                   /note="Epsin-1"
FT                   /id="PRO_0000074515"
FT   DOMAIN          12..144
FT                   /note="ENTH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00243"
FT   DOMAIN          183..202
FT                   /note="UIM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   DOMAIN          208..227
FT                   /note="UIM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   DOMAIN          233..252
FT                   /note="UIM 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   REPEAT          274..276
FT                   /note="1"
FT   REPEAT          294..296
FT                   /note="2"
FT   REPEAT          306..308
FT                   /note="3"
FT   REPEAT          319..321
FT                   /note="4"
FT   REPEAT          332..334
FT                   /note="5"
FT   REPEAT          349..351
FT                   /note="6"
FT   REPEAT          367..369
FT                   /note="7"
FT   REPEAT          377..379
FT                   /note="8"
FT   REPEAT          501..503
FT                   /note="1"
FT   REPEAT          517..519
FT                   /note="2"
FT   REPEAT          571..573
FT                   /note="3"
FT   REGION          149..186
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          264..283
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          274..379
FT                   /note="8 X 3 AA repeats of D-P-W"
FT   REGION          293..575
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          501..573
FT                   /note="3 X 3 AA repeats of N-P-F"
FT   MOTIF           401..410
FT                   /note="[DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif"
FT   COMPBIAS        455..469
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        510..533
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        537..575
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         8
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT   BINDING         11
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT   BINDING         25
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT   BINDING         30
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT   BINDING         63
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT   BINDING         73
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT   MOD_RES         382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6I3"
FT   MOD_RES         418
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6I3"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6I3"
FT   MOD_RES         420
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80VP1"
FT   MOD_RES         434
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6I3"
FT   MOD_RES         446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6I3"
FT   MOD_RES         453
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         459
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6I3"
FT   MOD_RES         463
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6I3"
FT   MOD_RES         469
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         472
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80VP1"
FT   MOD_RES         493
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6I3"
FT   MOD_RES         533
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80VP1"
FT   MUTAGEN         6
FT                   /note="L->E,H,Q: Reduces lipid binding."
FT                   /evidence="ECO:0000269|PubMed:12353027"
FT   MUTAGEN         8
FT                   /note="R->A: Strongly reduces lipid binding."
FT                   /evidence="ECO:0000269|PubMed:11161217"
FT   MUTAGEN         63
FT                   /note="R->L: Strongly reduces lipid binding. Abolishes
FT                   lipid binding; when associated with L-73."
FT                   /evidence="ECO:0000269|PubMed:11161217,
FT                   ECO:0000269|PubMed:12353027"
FT   MUTAGEN         72
FT                   /note="R->A: Abolishes ZNF145 binding."
FT                   /evidence="ECO:0000269|PubMed:11161217"
FT   MUTAGEN         73
FT                   /note="H->L: Abolishes lipid binding; when associated with
FT                   L-63."
FT                   /evidence="ECO:0000269|PubMed:12353027"
FT   MUTAGEN         76
FT                   /note="K->A: Strongly reduces lipid binding."
FT                   /evidence="ECO:0000269|PubMed:11161217"
FT   MUTAGEN         190
FT                   /note="L->A: Abolishes mono-ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:11919637"
FT   MUTAGEN         257..259
FT                   /note="LMD->AAA: Strongly reduces clathrin binding."
FT                   /evidence="ECO:0000269|PubMed:10692452"
FT   MUTAGEN         260..263
FT                   /note="LADV->AAAA: Strongly reduces clathrin binding."
FT                   /evidence="ECO:0000269|PubMed:10692452"
FT   HELIX           2..15
FT                   /evidence="ECO:0007829|PDB:1H0A"
FT   HELIX           19..27
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   STRAND          30..33
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           37..46
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           50..64
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           68..70
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           71..87
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           90..98
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           100..104
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           105..108
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           120..135
FT                   /evidence="ECO:0007829|PDB:1EYH"
FT   HELIX           137..155
FT                   /evidence="ECO:0007829|PDB:1EYH"
SQ   SEQUENCE   575 AA;  60158 MW;  D0B770F3B7AB5DDA CRC64;
     MSTSSLRRQM KNIVHNYSEA EIKVREATSN DPWGPSSSLM SEIADLTYNV VAFSEIMSMI
     WKRLNDHGKN WRHVYKAMTL MEYLIKTGSE RVSQQCKENM YAVQTLKDFQ YVDRDGKDQG
     VNVREKAKQL VALLRDEDRL REERAHALKT KEKLAQTATA SSAAVGSGPP PEAEQAWPQS
     SGEEELQLQL ALAMSKEEAD QPPSCGPEDD VQLQLALSLS REEHDKEERI RRGDDLRLQM
     AIEESKRETG GKEESSLMDL ADVFTTPAPP QASDPWGGPA SVPTAVPVAA AASDPWGAPA
     VPPAADPWGG AAPTPASGDP WRPAAPTGPS VDPWGGTPAP AAGEGPTSDP WGSADGGAPV
     SGPPSSDPWA PAPAFSDPWG GSPAKPSSNG TAVGGFDTEP DEFSDFDRLR TALPTSGSST
     GELELLAGEV PARSPGAFDM SGVGGSLAES VGSPPPAATP TPTPPTRKTP ESFLGPNAAL
     VDLDSLVSRP GPTPPGAKAS NPFLPSGAPA TGPSVTNPFQ PAPPATLTLN QLRLSPVPPV
     PGAPPTYISP LGGGPGLPPM MPPGPPAPNT NPFLL
//
